Read by QxMD icon Read

RMD Open

Niels W Boone, Alexandre Sepriano, Paul-Hugo van der Kuy, Rob Janknegt, Ralph Peeters, Robert B M Landewé
Objectives: We aimed to evaluate the effects of methotrexate (MTX) comedication added to biological disease-modifying antirheumatic drugs (bDMARD) on disease activity measures in patients with rheumatoid arthritis (RA) in routine care. Methods: Patients with RA on treatment with either bDMARDs or conventional synthetic DMARDs were included in this prospective cohort study. The effect of (time-varying) combination therapy with bDMARD and MTX compared with bDMARD monotherapy was tested in longitudinal generalised estimating equation models using as outcomes: (1) the likelihood to be in remission according to the 28-joint Disease Activity Score (DAS28) erythrocyte sedimentation rate (ESR) (<2...
2019: RMD Open
Ann-Sophie Vandendorpe, Kurt de Vlam, Rik Lories
Objectives: Psoriatic arthritis is a chronic inflammatory disease that affects the musculoskeletal system. It can include arthritis, spondylitis, dactylitis and enthesitis, and is strongly associated with the presence of psoriasis. The introduction of biological therapies as a treatment option has brought a significant improvement in disease control for patients with psoriatic arthritis. Here, we aimed to detect emerging differences in demographic and clinical characteristics of the psoriatic arthritis patient study population since the introduction of biologicals...
2019: RMD Open
Vibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, Philip J Mease, Dafna D Gladman, Linda Chen, Elizabeth Kudlacz, Joseph Wu, Joseph C Cappelleri, Thijs Hendrikx, Ming-Ann Hsu
Objectives: Tofacitinib is an oral Janus kinase inhibitor for treatment of psoriatic arthritis (PsA). Patient-reported outcomes (PROs) were evaluated in patients with PsA with inadequate responses to tumour necrosis factor inhibitors (TNFi-IR) in a 6-month, phase III randomised controlled trial (OPAL Beyond [NCT01882439]). Methods: Patients (N=394) received tofacitinib 5 or 10 mg twice daily or placebo (advancing to tofacitinib 5 or 10 mg twice daily at month 3)...
2019: RMD Open
Vibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, Philip J Mease, Dafna D Gladman, Daniela Graham, Cunshan Wang, Joseph C Cappelleri, Thijs Hendrikx, Ming-Ann Hsu
Objectives: Tofacitinib is an oral Janus kinase inhibitor for treatment of psoriatic arthritis (PsA). We evaluated patient-reported outcomes (PROs) in patients with PsA refractory to ≥1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR) and tumour necrosis factor inhibitor-naïve in a 12-month, phase III randomised controlled trial (OPAL Broaden [NCT01877668]). Methods: Patients (N=422) received tofacitinib 5 mg or 10 mg twice daily, adalimumab 40 mg subcutaneously every 2 weeks or placebo advancing to tofacitinib 5 mg or 10 mg twice daily at month 3...
2019: RMD Open
Janneke J de Winter, Jacqueline E Paramarta, Henriëtte M de Jong, Marleen G van de Sande, Dominique L Baeten
Objective: Spondyloarthritis (SpA) can encompass axial, peripheral and extra-articular disease manifestations. Patients are classified as axial or peripheral SpA depending on the presence or absence of current back pain, independently of the other disease manifestations. Therefore, we aimed to assess the percentage of patients with axial SpA with peripheral disease and how this peripheral disease contributes to the overall disease activity. Methods: Prevalence and disease activity of peripheral disease manifestations were assessed in a real-life observational cohort of 314 patients with the clinical diagnosis of SpA and fulfilling the Assessment of SpondyloArthritis international Society (ASAS) criteria...
2019: RMD Open
Sofie L M Blokland, Maarten R Hillen, Fréderique M van Vliet-Moret, Angela Bikker, Wilco de Jager, Aridaman Pandit, Aike A Kruize, Timothy R D J Radstake, Joel A G van Roon
Objective: To explore the potential of salivary gland biopsy supernatants (the secretome) as a novel tool to aid in stratification of patients with sicca syndrome and to study local immunopathology in Sjögren's syndrome. Methods: Labial salivary gland biopsies were incubated in saline for 1 hour. In these tissue supernatants from a discovery cohort (n=16) of patients with primary Sjögren's syndrome (pSS) and non-Sjögren's sicca (nSS), 101 inflammatory mediators were measured by Luminex...
2019: RMD Open
Juliane Schroeder, Kirsty Ross, Kathryn McIntosh, Shilan Jabber, Stuart Woods, Jenny Crowe, Janet Patterson Kane, James Alexander, Catherine Lawrence, Robin Plevin
Objectives: We have previously shown mitogen-activated protein kinase phosphatase 2 (MKP-2) to be a key regulator of proinflammatory cytokines in macrophages. In the study presented here, we investigated the role of MKP-2 in inflammatory arthritis with a particular focus on neutrophils. Methods: To achieve this, we subjected MKP-2 deficient and wild type mice to collagen antibody induced arthritis, an innate model of arthritis, and determined disease pathology. To further our investigation, we depleted neutrophils in a prophylactic and therapeutic fashion...
2019: RMD Open
Sofie L M Blokland, Maarten R Hillen, Catharina G K Wichers, Maili Zimmermann, Aike A Kruize, Timothy R D J Radstake, Jasper C A Broen, Joel A G van Roon
No abstract text is available yet for this article.
2019: RMD Open
Josef S Smolen, Dafna Gladman, H Patrick McNeil, Philip J Mease, Joachim Sieper, Maja Hojnik, Pascal Nurwakagari, John Weinman
Objective: This analysis explored the association of treatment adherence with beliefs about medication, patient demographic and disease characteristics and medication types in rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS) to develop adherence prediction models. Methods: The population was a subset from ALIGN, a multicountry, cross-sectional, self-administered survey study in adult patients (n=7328) with six immune-mediated inflammatory diseases who were routinely receiving systemic therapy...
2019: RMD Open
Luca Iaccarino, Rosaria Talarico, Carlo Alberto Scirè, Zahir Amoura, Gerd Burmester, Andrea Doria, Karim Faiz, Charissa Frank, Eric Hachulla, Miguel Hie, David Launay, Carlomaurizio Montecucco, Sara Monti, Luc Mouthon, Angela Tincani, Paola Toniati, Pieter Martin Van Hagen, Ronald F Van Vollenhoven, Stefano Bombardieri, Ulf Mueller-Ladner, Matthias Schneider, Vanessa Smith, Maurizio Cutolo, Marta Mosca, Tobias Alexander
Immunoglobulin G4-related diseases (IgG4-RD) are a group of chronic relapsing-remitting inflammatory conditions, characterised by tissue infiltration with lymphocytes and IgG4-secreting plasma cells, fibrosis and a usually favourable response to steroids. In this narrative review, we summarise the results of a systematic literature research, which was performed as part of the European Reference Network ReCONNET, aimed at evaluating existing clinical practice guidelines (CPGs) and recommendations in IgG4-RD...
2018: RMD Open
Julia Unger, Polina Putrik, Frank Buttgereit, Daniel Aletaha, Gerolamo Bianchi, Johannes W J Bijlsma, Annelies Boonen, Nada Cikes, João Madruga Dias, Louise Falzon, Axel Finckh, Laure Gossec, Tore K Kvien, Eric L Matteson, Francisca Sivera, Tanja A Stamm, Zoltan Szekanecz, Dieter Wiek, Angela Zink, Christian Dejaco, Sofia Ramiro
Objective: To summarise the available information on physician workforce modelling, to develop a rheumatology workforce prediction risk of bias tool and to apply it to existing studies in rheumatology. Methods: A systematic literature review (SLR) was performed in key electronic databases (1946-2017) comprising an update of an SLR in rheumatology and a hierarchical SLR in other medical fields. Data on the type of workforce prediction models and the factors considered in the models were extracted...
2018: RMD Open
Christian Dejaco, Polina Putrik, Julia Unger, Daniel Aletaha, Gerolamo Bianchi, Johannes W Bijlsma, Annelies Boonen, Nada Cikes, Axel Finckh, Laure Gossec, Tore K Kvien, Joao Madruga Dias, Eric L Matteson, Francisca Sivera, Tanja A Stamm, Zoltan Szekanecz, Dieter Wiek, Angela Zink, Sofia Ramiro, Frank Buttgereit
Objective: Current methods used for forecasting workforce requirements in rheumatology are disparate, as are the parameters incorporated into workforce projection studies. The objective of these European League Against Rheumatism (EULAR points to consider (PTC) is to guide future workforce studies in adult rheumatology in order to produce valid and reliable manpower estimates. Methods: The EULAR Standardised Operating Procedures were followed. A multidisciplinary task force with experts including patients with rheumatic diseases from 11 EULAR countries and the USA was assembled...
2018: RMD Open
Denis Poddubnyy, Johanna Callhoff, Inge Spiller, Joachim Listing, Juergen Braun, Joachim Sieper, Martin Rudwaleit
Objective: Inflammatory back pain (IBP), the key symptom of axial spondyloarthritis (axSpA), including ankylosing spondylitis, has been proposed as a screening test for patients presenting with chronic back pain in primary care. The diagnostic accuracy of IBP in the rheumatology setting is unknown. Methods: Six rheumatology centres, representing secondary and tertiary rheumatology care, included routinely referred patients with consecutive chronic back pain with suspicion of axSpA...
2018: RMD Open
Yousra J Dakkak, Désirée M van der Heijde, Monique Reijnierse, Annette H M van der Helm-van Mil
Objective: MRI depicts inflammation and structural damage in rheumatoid arthritis (RA). The validity of MRI-scoring of wrist-joints and metacarpophalangeal-joints according to the RA MRI score(RAMRIS) has been demonstrated. The Outcomes in Rheumatology Clinical Trials (OMERACT) RAMRIS Working Group recently called for validation of the RAMRIS of the metatarsophalangeal (MTP)-joints. Therefore, a systematic literature review was performed to test if the RAMRIS applied to the MTP-joints meets the OMERACT Filter of Truth, Discrimination and Feasibility...
2018: RMD Open
Eric Toussirot, Philippe Saas
No abstract text is available yet for this article.
2018: RMD Open
Tsukasa Matsubara, Hiroshi Inoue, Toshihiro Nakajima, Kazuhide Tanimura, Akira Sagawa, Yukio Sato, Kei Osano, Shuji Nagano, Yukitaka Ueki, Tadamasa Hanyu, Koichi Hashizume, Norihito Amano, Yoshiya Tanaka, Tsutomu Takeuchi
Objectives: To evaluate efficacy and safety of abatacept+methotrexate (MTX) in biologic-naive, anticitrullinated protein antibody (ACPA)-positive Japanese patients with active rheumatoid arthritis (RA) and early erosion versus placebo+MTX. Methods: In this phase IV, multicentre, double-blind study (NCT01758198), patients were randomised (1:1) to receive intravenous abatacept (~10 mg/kg) or placebo, plus MTX (≥6 mg/week). Primary efficacy objectives were to compare American College of Rheumatology 20 (ACR20) response rates at week 16 and mean change from baseline in van der Heijde-modified total Sharp score (vdH-mTSS) at week 24 between abatacept+MTX and placebo+MTX groups...
2018: RMD Open
Lotta Ljung, Peter Ueda, Katherine P Liao, Jeffrey D Greenberg, Carol J Etzel, Daniel H Solomon, Johan Askling
Background: Cardiovascular (CV) risk stratification for patients with rheumatoid arthritis (RA) should facilitate evidence-based management. Prior work has derived an internally validated a CV risk score, the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis (ERS-RA), using US data. The aim of this study was to perform an external validation among unselected patients with RA from Europe. Methods: Three large, partially overlapping, cohorts of patients with RA from the Swedish Rheumatology Quality register were identified for external validation, two with information on smoking and two with close to 10 years of median follow-up...
2018: RMD Open
Åsa Lundgren-Nilsson, Anna Dencker, Annie Palstam, Gert Person, Mike C Horton, Reuben Escorpizo, Ayse A Küçükdeveci, Sehim Kutlay, Atilla H Elhan, Gerold Stucki, Alan Tennant, Philip G Conaghan
Introduction: Patient-reported outcome measures (PROM) or self-completed questionnaires have been used to report outcomes in osteoarthritis (OA) for over 35 years. Choices will always need to be made about what should be measured and, if relevant, what would be the most appropriate PROM to use. The current study aims to describe the available PROMs used in OA and their performance quality, so that informed choices can be made about the most appropriate PROM for a particular task. Methods: The study included a systematic search for PROMs that have been in use over 17 years (period 2000-2016), and to catalogue their psychometric properties, and to present the evidence in a user-friendly fashion...
2018: RMD Open
Anne-Kathrin Rausch Osthoff, Carsten Bogh Juhl, Keegan Knittle, Hanne Dagfinrud, Emalie Hurkmans, Juergen Braun, Jan Schoones, Theodora P M Vliet Vlieland, Karin Niedermann
Objective: To evaluate the effectiveness of exercise and physical activity (PA) promotion on cardiovascular fitness, muscle strength, flexibility, neuromotor performance (eg, balance) and daily PA in people with rheumatoid arthritis (RA), spondyloarthritis (SpA) and hip/knee osteoarthritis (HOA/KOA). Methods: systematic review (SR) and meta-analysis (MA) were performed searching the databases PubMed/Medline, CENTRAL, Embase, Web of Science, Emcare and PsycInfo until April 2017...
2018: RMD Open
Farah Tamirou, Laurent Arnaud, Rosaria Talarico, Carlo Alberto Scirè, Tobias Alexander, Zahir Amoura, Tadej Avcin, Alessandra Bortoluzzi, Ricard Cervera, Fabrizio Conti, Alain Cornet, Hervé Devilliers, Andrea Doria, Micol Frassi, Micaela Fredi, Marcello Govoni, Frederic Houssiau, Ana Lladò, Carla Macieira, Thierry Martin, Laura Massaro, Maria Francisca Moraes-Fontes, Cristina Pamfil, Sabrina Paolino, Chiara Tani, Sander W Tas, Maria Tektonidou, Angela Tincani, Ronald F Van Vollenhoven, Stefano Bombardieri, Gerd Burmester, Fonseca João Eurico, Ilaria Galetti, Eric Hachulla, Ulf Mueller-Ladner, Matthias Schneider, Vanessa Smith, Maurizio Cutolo, Marta Mosca, Nathalie Costedoat-Chalumeau
Systemic lupus erythematosus (SLE) is the paradigm of systemic autoimmune diseases characterised by a wide spectrum of clinical manifestations with an unpredictable relapsing-remitting course. The aim of the present work was to identify current available clinical practice guidelines (CPGs) for SLE, to provide their review and to identify physicians' and patients' unmet needs. Twenty-three original guidelines published between 2004 and 2017 were identified. Many aspects of disease management are covered, including global disease management, lupus nephritis and neuropsychiatric involvement, management of pregnancies, vaccinations and comorbidities monitoring...
2018: RMD Open
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"